Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Mon 19 Nov 2007, 9:08 ENL - Enaleni - Concludes disposal of bioharmony a
ENL
 ENL                                                                             
ENL - Enaleni - Concludes disposal of bioharmony and muscle science businesses  
Enaleni Pharmaceuticals Limited                                                 
(Incorporated in the Republic of South Africa)                                  
(Registration number 2002/018027/06)                                            
JSE code: ENL ISIN: ZAE000067740                                                
("Enaleni")                                                                     
ENALENI PHARMACEUTICALS LIMITED CONCLUDES DISPOSAL OF BIOHARMONY AND MUSCLE     
SCIENCE BUSINESSES                                                              
1    Introduction                                                               
Shareholders are advised that Enaleni has concluded two Sale of Shares and      
Claims Agreements effective 30 November 2007 with Arcay Merchant (Proprietary)  
Limited ("Arcay"), the corporate advisors to Wellco Health Limited ("Wellco").  
Arcay will purchase all the shares in, and claims against, including the        
Intellectual Property, of Aldabri 53 (Proprietary) Limited trading as Muscle    
Science ("Muscle Science") (of which Enaleni owns 67%) and Bioharmony           
(Proprietary) Limited ("Bioharmony") ("the disposals"). It is Arcay`s intention,
following the successful restructuring of Wellco as announced on SENS on 25     
October 2007, that these companies will be acquired by Wellco.                  
2    Consideration                                                              
The consideration payable for the disposals are R26.6 million for Bioharmony and
R8.6 million for Enaleni`s 67% shareholding in Muscle Science, which is to be   
settled in cash.                                                                
3    Conditions Precedent                                                       
There are no outstanding conditions precedent to the disposals.                 
4    Financial Effects                                                          
There will be no material effect on earnings, headline earnings, net asset value
or net tangible asset value per share.                                          
This concludes the disposal of our non-core assets in line with the Group`s     
strategy of focusing on pharmaceuticals.                                        
Durban                                                                          
19 November 2007                                                                
Investment bank and sponsor                                                     
Nedbank Capital                                                                 
Attorneys to Enaleni Pharmaceuticals Limited                                    
Deneys Reitz                                                                    
Date: 19/11/2007 09:08:12 Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
[  Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: